Compare ARVN & KIDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | KIDS |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 512.4M |
| IPO Year | 2018 | 2016 |
| Metric | ARVN | KIDS |
|---|---|---|
| Price | $9.20 | $24.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 9 |
| Target Price | $15.05 | ★ $24.67 |
| AVG Volume (30 Days) | ★ 878.8K | 202.9K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | $98,049,000.00 |
| Revenue This Year | N/A | $14.07 |
| Revenue Next Year | N/A | $11.85 |
| P/E Ratio | $5.28 | ★ N/A |
| Revenue Growth | N/A | ★ 37.95 |
| 52 Week Low | $6.96 | $14.42 |
| 52 Week High | $14.22 | $25.35 |
| Indicator | ARVN | KIDS |
|---|---|---|
| Relative Strength Index (RSI) | 64.01 | 75.13 |
| Support Level | $7.90 | $15.66 |
| Resistance Level | $9.65 | N/A |
| Average True Range (ATR) | 0.40 | 0.97 |
| MACD | 0.07 | 0.35 |
| Stochastic Oscillator | 75.50 | 87.35 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.